Alcohol withdrawal: Difference between revisions
imported>Robert Badgett |
imported>Robert Badgett |
||
Line 43: | Line 43: | ||
|} | |} | ||
[[Randomized controlled trial]]s have found benefit from [[adrenergic beta-receptor blockader]]s such as [[atenolol]]<ref name="pmid2863754">{{cite journal |author=Kraus ML, Gottlieb LD, Horwitz RI, Anscher M |title=Randomized clinical trial of atenolol in patients with alcohol withdrawal |journal=N. Engl. J. Med. |volume=313 |issue=15 |pages=905-9 |year=1985 |pmid=2863754 |doi=}}</ref> and [[clonidine]].<ref name="pmid3300587">{{cite journal |author=Baumgartner GR, Rowen RC |title=Clonidine vs chlordiazepoxide in the management of acute alcohol withdrawal syndrome |journal=Arch. Intern. Med. |volume=147 |issue=7 |pages=1223-6 |year=1987 |pmid=3300587 |doi=}}</ref> | [[Randomized controlled trial]]s have found benefit from [[adrenergic beta-receptor blockader]]s such as [[atenolol]]<ref name="pmid2863754">{{cite journal |author=Kraus ML, Gottlieb LD, Horwitz RI, Anscher M |title=Randomized clinical trial of atenolol in patients with alcohol withdrawal |journal=N. Engl. J. Med. |volume=313 |issue=15 |pages=905-9 |year=1985 |pmid=2863754 |doi=}}</ref> and [[clonidine]].<ref name="pmid3300587">{{cite journal |author=Baumgartner GR, Rowen RC |title=Clonidine vs chlordiazepoxide in the management of acute alcohol withdrawal syndrome |journal=Arch. Intern. Med. |volume=147 |issue=7 |pages=1223-6 |year=1987 |pmid=3300587 |doi=}}</ref> In the major trial, atenolol was given to patients without contraindications at a dose of 50 mg if the pulse was 50-79 and 100 mg if the pulse was 80 or more.<ref name="pmid2863754"/> Clonidine was administered to patients without contraindications as 0.2 mg per dose with the schedule of day 1 at 9pm; day 2 at 9am, 1pm, and 6pm; day 3 9am and 6pm; and day 4 at 9am.<ref name="pmid3300587"/> | ||
A factorial [[randomized controlled trial]]<ref name="pmid7004240">{{cite journal |author=Zilm DH, Jacob MS, MacLeod SM, Sellers EM, Ti TY |title=Propranolol and chlordiazepoxide effects on cardiac arrhythmias during alcohol withdrawal |journal=Alcohol. Clin. Exp. Res. |volume=4 |issue=4 |pages=400-5 |year=1980 |pmid=7004240 |doi= |issn=}}</ref> has been misinterpreted leading to concerns that beta-blockers are associated with hallucinations.<ref name="pmid15249349">{{cite journal |author=Mayo-Smith MF, Beecher LH, Fischer TL, ''et al'' |title=Management of alcohol withdrawal delirium. An evidence-based practice guideline |journal=Arch. Intern. Med. |volume=164 |issue=13 |pages=1405-12 |year=2004 |pmid=15249349 |doi=10.1001/archinte.164.13.1405}}</ref> However, the table at right shows that in the factorial study, the hallucinations were associated with the absence of chlordiazepoxide and not the presence of propanolol. The combination of both propanolol and chlordiazepoxide gave the best combination of reduction in withdrawal symptoms and arrhythmias.<ref name="pmid7004240"/> | A factorial [[randomized controlled trial]]<ref name="pmid7004240">{{cite journal |author=Zilm DH, Jacob MS, MacLeod SM, Sellers EM, Ti TY |title=Propranolol and chlordiazepoxide effects on cardiac arrhythmias during alcohol withdrawal |journal=Alcohol. Clin. Exp. Res. |volume=4 |issue=4 |pages=400-5 |year=1980 |pmid=7004240 |doi= |issn=}}</ref> has been misinterpreted leading to concerns that beta-blockers are associated with hallucinations.<ref name="pmid15249349">{{cite journal |author=Mayo-Smith MF, Beecher LH, Fischer TL, ''et al'' |title=Management of alcohol withdrawal delirium. An evidence-based practice guideline |journal=Arch. Intern. Med. |volume=164 |issue=13 |pages=1405-12 |year=2004 |pmid=15249349 |doi=10.1001/archinte.164.13.1405}}</ref> However, the table at right shows that in the factorial study, the hallucinations were associated with the absence of chlordiazepoxide and not the presence of propanolol. The combination of both propanolol and chlordiazepoxide gave the best combination of reduction in withdrawal symptoms and arrhythmias.<ref name="pmid7004240"/> |
Revision as of 12:39, 3 April 2008
Template:TOC-right Alcohol withdrawal is a group of syndromes that may occur after cessation of drinking ethanol alcohol.[1][2][3]
Classification
Autonomic hyperactivity
Withdrawal may cause hyperactivity of the sympathetic nervous system.
Seizures
Alcohol withdrawal seizures is a "condition where seizures occur in association with ethanol abuse (alcoholism) without other identifiable causes. Seizures usually occur within the first 6-48 hours after the cessation of alcohol intake, but may occur during periods of alcohol intoxication. Single generalized tonic-clonic motor seizures are the most common subtype, however, status epilepticus may occur".[4][5]
Delirium
Alcohol withdrawal delirium,formerly called delerium tremens, is an "acute organic mental disorder induced by cessation or reduction in chronic alcohol consumption. Clinical characteristics include confusion; delusions; vivid hallucinations; tremor; agitation; insomnia; and signs of autonomic hyperactivity (e.g., elevated blood pressure and heart rate, dilated pupils, and diaphoresis). This condition may occasionally be fatal."[6][7]
Treatment
Benzodiazepines
Benzodiazepines such as diazepam (Valium), lorazepam (Ativan) or oxazepam (Serax) are the most commonly used drugs used to reduce alcohol withdrawal symptoms. There are several treatment patterns in which it is used.
- One option takes into consideration the varying degrees of tolerance. In it, a standard dose of the benzodiazepine is given every half hour until light sedation is reached. Once a baseline dose is determined, the medication is tapered over the ensuing 3-10 days.
- Another option is to defer treatment until symptoms occur.[8][9] A non-randomized, before and after, observational study found that symptom triggered therapy was advantageous.[10]
Dosing of the benzodiazepines can be guided by the CIWA-Ar scale.[11] The scale is available online (see external links below).
Regarding the choice of benzodiazepine:
- Chlordiazepoxide (Librium®) is the benzodiazepine of choice in uncomplicated alcohol withdrawal. [12]
- Lorazepam or diazepam are available parenterally for patients who cannot safely take medications by mouth.
- Lorazepam and oxazepam may be best in patients with cirrhosis (shorter half life).
Adrenergic antagonists
Chlordiazepoxide | |||
---|---|---|---|
Given | Not given | ||
Propranolol | Given | 1 | 4 |
Not given | 0 | 4 | |
Notes: 1. There were 15 patients in each group. 2. Not shown is the arrhythmia scores, |
Randomized controlled trials have found benefit from adrenergic beta-receptor blockaders such as atenolol[13] and clonidine.[14] In the major trial, atenolol was given to patients without contraindications at a dose of 50 mg if the pulse was 50-79 and 100 mg if the pulse was 80 or more.[13] Clonidine was administered to patients without contraindications as 0.2 mg per dose with the schedule of day 1 at 9pm; day 2 at 9am, 1pm, and 6pm; day 3 9am and 6pm; and day 4 at 9am.[14]
A factorial randomized controlled trial[15] has been misinterpreted leading to concerns that beta-blockers are associated with hallucinations.[1] However, the table at right shows that in the factorial study, the hallucinations were associated with the absence of chlordiazepoxide and not the presence of propanolol. The combination of both propanolol and chlordiazepoxide gave the best combination of reduction in withdrawal symptoms and arrhythmias.[15]
A case report shows that beta-blockers may remove signs of hyperactivity of the sympathetic nervous system thus leading to overlooking a diagnosis of delirium tremens in a chronic alcholic with hallucinations after stopping alcohol.[16] Thus clinicians should not require the presence of sympathetic hyperactivity in diagnosing delirium tremens in a patient receiving beta-blockers.
Carbamazepine
A randomized controlled trial has found benefit from carbamazepine.[17]
Other drugs
Sodium oxybate is the sodium salt of gamma-hydroxybutyric acid (GHB). It has been studied for both acute alcohol withdrawal[18] and medium to long-term detoxification[19]. This drug enhances neurotransmission by the inhibitory neurotransmitter gamma aminobutyric acid (GABA) and reduces levels of the excitatory neurotransmitter glutamate.
Baclofen has been shown in animal studies and in small human studies to enhance detoxification[20] and maybe reduce craving[21]. This drug acts as a GABA B receptor agonist.
Some hospitals administer alcohol to prevent alcohol withdrawal although there are potential problems with this practice.[22]
References
- ↑ 1.0 1.1 Mayo-Smith MF, Beecher LH, Fischer TL, et al (2004). "Management of alcohol withdrawal delirium. An evidence-based practice guideline". Arch. Intern. Med. 164 (13): 1405-12. DOI:10.1001/archinte.164.13.1405. PMID 15249349. Research Blogging.
- ↑ Mayo-Smith MF, Beecher LH, Fischer TL, Gorelick DA, Guillaume JL, Hill A, Jara G, Kasser C, Melbourne J. (2004). Management of alcohol withdrawal delirium. An evidence-based practice guideline. (English). National Guidelines Clearinghouse. Retrieved on 2008-04-03.
- ↑ Mayo-Smith MF (1997). "Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal". JAMA 278 (2): 144-51. PMID 9214531. [e] Full text at OVID
- ↑ Anonymous (2024), Alcohol withdrawal seizures (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Ropper, Allan H.; Adams, Raymond Delacy; Victor, Maurice (1997). Principles of Neurology. New York: McGraw-Hill, Health Professions Division, 1174. ISBN 0-07-067439-6.
- ↑ Anonymous (2024), Alcohol withdrawal delirium (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Ropper, Allan H.; Adams, Raymond Delacy; Victor, Maurice (1997). Principles of Neurology. New York: McGraw-Hill, Health Professions Division, 1175. ISBN 0-07-067439-6.
- ↑ Saitz R, Mayo-Smith MF, Roberts MS, Redmond HA, Bernard DR, Calkins DR (1994). "Individualized treatment for alcohol withdrawal. A randomized double-blind controlled trial". JAMA 272 (7): 519-23. PMID 8046805. [e]
- ↑ Daeppen JB, Gache P, Landry U, et al (2002). "Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial". Arch. Intern. Med. 162 (10): 1117-21. PMID 12020181. [e]
- ↑ Jaeger TM, Lohr RH, Pankratz VS (2001). "Symptom-triggered therapy for alcohol withdrawal syndrome in medical inpatients". Mayo Clin. Proc. 76 (7): 695-701. PMID 11444401. [e]
- ↑ Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM (1989). "Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar)". British journal of addiction 84 (11): 1353-7. PMID 2597811. [e]
- ↑ Raistrick, D, Heather N & Godfrey C (2006) "Review of the Effectiveness of Treatment for Alcohol Problems" National Treatment Agency for Substance Misuse, London http://www.nta.nhs.uk/publications/documents/nta_review_of_the_effectiveness_of_treatment_for_alcohol_problems_fullreport_2006_alcohol2.pdf
- ↑ 13.0 13.1 Kraus ML, Gottlieb LD, Horwitz RI, Anscher M (1985). "Randomized clinical trial of atenolol in patients with alcohol withdrawal". N. Engl. J. Med. 313 (15): 905-9. PMID 2863754. [e]
- ↑ 14.0 14.1 Baumgartner GR, Rowen RC (1987). "Clonidine vs chlordiazepoxide in the management of acute alcohol withdrawal syndrome". Arch. Intern. Med. 147 (7): 1223-6. PMID 3300587. [e]
- ↑ 15.0 15.1 Zilm DH, Jacob MS, MacLeod SM, Sellers EM, Ti TY (1980). "Propranolol and chlordiazepoxide effects on cardiac arrhythmias during alcohol withdrawal". Alcohol. Clin. Exp. Res. 4 (4): 400-5. PMID 7004240. [e]
- ↑ Zechnich RJ (1982). "Beta blockers can obscure diagnosis of delirium tremens". Lancet 1 (8280): 1071-2. PMID 6122874. [e]
- ↑ Malcolm R, Ballenger JC, Sturgis ET, Anton R (1989). "Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal". The American journal of psychiatry 146 (5): 617-21. PMID 2653057. [e]
- ↑ Nava F, Premi S, Manzato E, Campagnola W, Lucchini A, Gessa GL (2007). "Gamma-hydroxybutyrate reduces both withdrawal syndrome and hypercortisolism in severe abstinent alcoholics: an open study vs. diazepam". Am J Drug Alcohol Abuse 33 (3): 379-92. DOI:10.1080/00952990701315046. PMID 17613965. Research Blogging.
- ↑ Caputo F, Addolorato G, Stoppo M, et al (2007). "Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomised comparative study". Eur Neuropsychopharmacol 17 (12): 781-9. DOI:10.1016/j.euroneuro.2007.04.008. PMID 17611081. Research Blogging.
- ↑ Addolorato G, Caputo F, Capristo E, et al (2002). "Rapid suppression of alcohol withdrawal syndrome by baclofen". Am. J. Med. 112 (3): 226-9. PMID 11893350. [e]
- ↑ Addolorato G, Caputo F, Capristo E, et al (2002). "Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study". Alcohol Alcohol. 37 (5): 504-8. PMID 12217947. [e]
- ↑ Blondell RD, Dodds HN, Blondell MN, et al (2003). "Ethanol in formularies of US teaching hospitals". JAMA 289 (5): 552. PMID 12578486. [e]
External links
- CIWA-AR - this is freely available without copyright restrictions from